Our study thus confirms the importance of the pre-therapeutic determination of the UGT1A1 genotype for predicting irinotecan toxicity, and indicates that heterozygous patients may be also at increased risk for neutropoenia. The gene discussed is UGT1A1; the disease is Decreased total neutrophil count.